feedback

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: July 15, 2020
Expires: July 14, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Describe the epidemiology and demography of wild-type and hereditary ATTR amyloidosis with review of special populations in whom the disease is more prevalent.
  2. Recognize the pathophysiology that leads to amyloid deposition in different organ systems, forming the basis for understanding treatment approaches.
  3. Describe the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys.
  4. Outline the diagnostic approach to follow when treating a patient with suspected ATTR amyloidosis with focus on imaging and scenarios that require invasive biopsy.

Activity Description

The purpose of this webinar is to discuss the epidemiology and demography of wild-type and hereditary ATTR amyloidosis, with a review of special populations in whom the disease is more prevalent, as well as insights into the pathophysiology that leads to amyloid deposition in different organ systems, such as the heart, nervous system, gastro-intestinal tract, and kidneys, forming the basis for understanding treatment approaches.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention project is to improve the care of patients with transthyretin amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Hidden in Plain Sight: The Clinical Presentation of ATTR
10 minutes – Q & A

Presenters

Frederick (Rick) L. Ruberg, MD
Director, Advanced Cardiovascular Imaging
Associate Professor of Medicine
Program Associate Director, Cardiovascular
Boston University School of Medicine
Boston, MA


Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
Family Medicine
University of Florida
Gainesville, FL

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant - Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 07/15/2020
TERMINATION DATE: 07/14/2023
LAST REVIEW DATE: July 2020
ACCREDITATION TERMS:
Joint Accreditation: 07/15/2020 – 07/14/2023
CAPCE: 07/15/2020 – 07/14/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:

View the content in its entirety.

Complete a post-test with a minimum score of 75%.

Complete a survey of your learning experience.

Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.